TipRanks on MSN

Amgen’s Phase 3 Study on Rocatinlimab: A Potential Game-Changer for Prurigo Nodularis

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study ...

Biogen and Denali’s New Study on LRRK2-Associated Parkinson’s Disease: What Investors Need to Know

Biogen Inc. ( (BIIB) ), Denali Therapeutics ( (DNLI)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data ...

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the ...
ascopubs.org

A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).

Phase I/II study to evaluate the feasibility and efficacy of sequential abemaciclib and gemcitabine treatment in patients with retinoblastoma (Rb)-positive leiomyosarcoma (LMS) and dedifferentiated ...
TipRanks on MSN

Oruka Therapeutics’ Promising Psoriasis Study: What Investors Need to Know

Oruka Therapeutics, Inc. (($ORKA)) announced an update on their ongoing clinical study. Oruka Therapeutics, Inc. is conducting a study titled ‘A ...

Jazz Pharmaceuticals Advances ONC201 Study for Glioma Treatment

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

For more information about the 14 th Annual Acute Leukemia Meeting, please visit the meeting website. About Moleculin Biotech, Inc.
ascopubs.org

QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD ...

Hydroxyurea vs. hypomethylating vs. other agents in chronic myelomonocytic leukemia: A retrospective inspection of treatment strategies among 457 Mayo Clinic patients. This is an ASCO Meeting Abstract ...